
Opinion|Videos|December 20, 2024
Additional Toxicities in GPRC5D-Directed Bispecifics for RRMM
Author(s)Binod Dhakal, MD, MS
Panelist discusses how, based on the patient achieving sCR with emerging oral, skin, and nail toxicities, panelist would recommend initiating supportive care, including oral hygiene protocols, topical treatments, and prophylactic nail care. These toxicities are generally less severe than those of BCMA-targeted bispecifics, which often present with more systemic CRS and neurotoxicity.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- After the first month of treatment, the patient achieved stringent complete response (sCR) but is experiencing the following symptoms: oral, skin, and nail toxicities.
- What mitigation strategies would you initiate for this patient?
- How do those toxicities compare with those of other bispecifics (ie, BCMA-directed) in this space?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































